
K-parenting 101: Baby's head sculpted in sleep
While flat head syndrome is a real condition caused by constant pressure on the back or side of a baby's head, South Korean parents often have additional concerns. They believe the shape of the head forms the foundation of the face and that a flat head can interfere with the development of the baby's facial features.
Since a baby's skull is still soft and developing, many Korean parents see infancy as a crucial window to shape a round, gently protruding back of the head, commonly called "jjanggu head," believing it will lead to a smaller, more sculpted face later in life.
'Jjanggu,' although best known as the Korean name for the popular Japanese animated character Shin-chan, is also a Korean word defined in dictionaries as a head shape characterized by a prominent forehead or occipital area.
To prevent flat head, many parents make a habit of regularly alternating their baby's sleeping position from one side to the other. Some position their newborns to sleep on their sides or even on their stomachs, to avoid putting pressure on the back of the baby's head. There are even side-sleeping pillows on the market designed for newborns to lie on their side and wrap their little arms around the cushion.
But many pediatricians in Korea and other countries strongly warn against putting babies to sleep on their stomachs or sides, as it has been directly linked to Sudden Infant Death Syndrome.
There have been numerous cases of infants dying while sleeping face-down. Just last year, a baby at a daycare center in Daegu died during a nap after being placed in a prone position following lunch.
Some parents, unwilling to choose between safety and aesthetics, turn to head-shaping pillows featuring a dip in the middle. They are advertised as softly cradling the baby's head and preventing flattening.
However, a local pediatrician surnamed Song says that those pillows are a product of Korea's beauty-obsessed parenting culture, calling them a form of "misleading marketing."
"In most cases, a baby's head shape naturally corrects itself with growth. Sleeping face-down can block a baby's airway or interfere with body temperature regulation, so it requires special caution," he said.
Next time you see a 'jjanggu' pillow online while shopping for a baby shower gift in Korea, remember that it's not about the anime character but about "K-beauty" starting in infancy.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Korea Herald
12 hours ago
- Korea Herald
Park Bom to step down from 2NE1 activities due to health concerns
Park Bom, a member of girl group 2NE1, will not be participating in the group's upcoming activities due to health issues, her agency announced Wednesday. 'We inform you that Park Bom will not be able to join 2NE1's future schedule,' D-Nation Entertainment said via social media. 'After receiving medical advice recommending sufficient rest and stability, we reached this decision after careful discussions.' 'We ask for your warm support for Park Bom's recovery, and we would be grateful if you could also cheer on Sandara Park, CL and Minzy, who will do their best to fill the void,' the company added. Concerns about Park's health and her ability to continue group activities have been raised in recent months. She has alarmed fans by posting heavily filtered selfies and making unverified personal claims online — including stating she is dating actor Lee Min-ho — raising questions about her health. The singer also abruptly canceled her appearance at the Waterbomb Busan festival on July 26, an unusual move in the tightly scheduled world of K-pop, where same-day cancellations are rare. Meanwhile, Park, alongside 2NE1 members, performed Saturday during the halftime show at a friendly football match between Tottenham Hotspur and Newcastle United FC at Seoul World Cup Stadium.


Korea Herald
3 days ago
- Korea Herald
Korean drug firms step up race to take on Wegovy, Mounjaro
Hanmi outpaces crosstown rivals with once-weekly GLP-1 shot, aiming for 2025 launch Korean pharmaceutical companies are rushing to develop their own alternatives to blockbuster weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Mounjaro, accelerating efforts to enter the booming obesity treatment market with competitively priced medications, improved tolerability and innovative delivery methods. Hanmi Pharmaceutical appears to be leading the race so far, as it has been carrying out Phase 3 clinical trials of Efpeglenatide, a glucagon-like peptide-1, or GLP-1, drug that can be injected once a week, in Korea since January this year. The drug developer plans to complete the third and final clinical studies in September, eyeing the launch of the weight-loss medication in the second half of next year. According to Hanmi, the drug uses a slow absorption method to offer improved tolerability and fewer gastrointestinal side effects. It also has reportedly displayed impacts in reducing cardiovascular and kidney disease risks by over 35 percent. A Hanmi official said the price of its weight-loss drug is expected to be lower than the imported ones such as Wegovy, as it will be produced at the company's local plant in Pyeongtaek, Gyeonggi Province. Hanmi is also concentrating on developing next-generation anti-obesity drugs. The company presented early-stage studies of new drug candidates HM15275 and HM17321 at the 85th Scientific Sessions of the American Diabetes Association held in Chicago in June. The findings for HM15275 show more rapid and effective weight loss in comparison to anti-obesity drugs currently available in the market, while patients on HM17321 have achieved fat loss and muscle gain at the same time. 'Hanmi's research capabilities and development expertise in obesity and metabolic diseases are not only the best in Korea, but are increasingly recognized on the global stage,' said Choi In-young, head of R&D at Hanmi. 'As the global pharmaceutical landscape continues to shift toward obesity therapeutics, we will continue to strengthen our position as a true front-runner in this field.' HK Inno.N obtained approval for an Investigational New Drug plan to conduct Phase 3 clinical trials of Ecnoglutide, a GLP-1 receptor agonist, in Korea from the Ministry of Food and Drug Safety. HK Inno.N got the license for Ecnoglutide from China's Sciwind Biosciences last year, securing exclusive rights to develop and commercialize the drug candidate in Korea. According to recently released findings of Ecnoglutide's Phase 3 clinical studies in China, the drug demonstrated that people lost between 9 and 13 percent of their body weight on average after 40 weeks of treatment. HK Inno.N plans to complete Korean Phase 3 clinical trials by May 2028 to gear up for domestic commercialization. While the administration of anti-obesity drugs has been mostly focused on injections, some drugmakers are turning to develop drugs that are easier to take. Yuhan has partnered with Inventage Lab, a Korean biotechnology firm specializing in long-acting injectables, to develop IVL3021, a GLP-1 type medication that only requires an injection once a month, unlike the market-leading Wegovy's weekly dosage. They are also developing IVL3027, a Semaglutide-based oral medication candidate to help people lose weight, by using Inventage Lab's microsphere technology to maintain the stable release of the drug. Ildong Pharmaceutical's research and development company Yunobia is also developing an oral GLP-1 receptor agonist-based oral medication candidate code-named ID110521156. According to its recently released findings, Phase 1 clinical studies showed that obese participants achieved an average 6.9 percent weight loss over a four-week period, with a maximum weight cut of 11.9 percent. Daewon Pharmaceutical joined hands with local microneedle technology firm Raphas to develop DW1022, a weight loss patch candidate. After obtaining health authorities' approval for a Korean Phase 1 clinical trial in March last year, the company recently completed first phase studies while showcasing excellent tolerability and safety. Daewon Pharmaceutical said the patch-type drug candidate using Semaglutide, the main component of Wegovy, showed biological equivalence with the control group that used Wegovy with no differences in safety. According to Morgan Stanley, the global market for obesity medications posted approximately $15 billion in sales last year and could reach as high as $150 billion in 2035. Worldwide market intelligence estimates that about 11 percent of the global population, or 1.3 billion people, could be eligible for anti-obesity drugs, with adoption rates among those eligible currently only at about 3 percent in the US and 1 percent in other countries. 'The adoption of weight-loss drugs is likely to accelerate in a pattern similar to structural changes in the technology cycle, such as the introduction of smartphones,' Morgan Stanley noted in a report. 'Patients' use will increase as they become more familiar and comfortable with the new products and as manufacturers address hurdles in production, distribution and regulatory issues.'


Korea Herald
3 days ago
- Korea Herald
Korea's anti-obesity drug race in 2 minutes
A lot of people are trying to lose weight for a healthier life, a better appearance or self-satisfaction — but losing weight is not all that easy. For those struggling to cut fat, anti-obesity medications are practically magical. With the global weight-loss drug market expected to reach $150 billion in 2035, Korean pharmaceutical companies are rushing to come up with their own anti-obesity medications. Here's how far they have come so far. Yuhan Ildong Pharmaceutical Daewon Pharmaceutical Why it matters